Neutrophil-targeted delivery of circSCMH1 unlocks an acute anti-thromboinflammatory function to restore microvascular perfusion in stroke

This study demonstrates that neutrophil-targeted delivery of circSCMH1 via lipid nanoparticles mitigates futile recanalization in stroke by suppressing neutrophil-mediated thromboinflammation and restoring microvascular perfusion, offering a novel adjunctive therapy for endovascular thrombectomy.

The Gist

The Big Problem: The "Traffic Jam" After the Accident

Imagine a major highway (your brain's main artery) gets blocked by a giant rock (a blood clot). This causes a traffic jam that stops cars (blood) from reaching a neighborhood (part of the brain). This is a stroke.

Doctors have a great tool called Endovascular Thrombectomy (EVT). Think of it as a specialized tow truck that drives down the highway, grabs the rock, and pulls it out. The main road is clear! The big arteries are open.

But here's the tragedy: Even though the main road is open, the neighborhood is still in ruins. Why? Because of Futile Recanalization (FR).

When the big rock is removed, a chaotic crowd of emergency responders (white blood cells called neutrophils) rushes in. Instead of helping, they panic. They start building their own roadblocks, releasing sticky nets (called NETs) that clog up the tiny side streets (capillaries). The main road is open, but the tiny streets are jammed. No blood can get to the houses, and the brain tissue dies.

The Missing Piece: The "Peacekeeper" Molecule

The researchers discovered a tiny, circular piece of genetic code called circSCMH1.

• Old View: Scientists thought this molecule was like a "construction foreman" that only showed up weeks later to help rebuild the neighborhood after the damage was done.
• New Discovery: This paper found that in patients who had the "traffic jam" problem (FR), this "Peacekeeper" molecule was missing right at the scene of the accident. Without it, the emergency responders (neutrophils) went wild and built those sticky roadblocks.

The Solution: A "Trojan Horse" Delivery System

The problem was that if you just gave the patient a pill of this "Peacekeeper" molecule, it would get lost in the body or eaten by the liver before it could reach the angry neutrophils. It needed a way to sneak inside the troublemakers.

The team built a high-tech delivery truck (called circSCMH1@pepLNP).

• The Truck: It's a tiny bubble (lipid nanoparticle) carrying the "Peacekeeper" molecule.
• The GPS: The truck is coated with a special sticker (a peptide) that acts like a magnet. It specifically looks for the "Uniform" worn by the angry neutrophils (Formyl Peptide Receptors).
• The Mission: The truck drives through the bloodstream, finds the angry neutrophils, locks onto them, and delivers the "Peacekeeper" directly inside their cell.

What Happened When They Used the Truck?

When they tested this on mice with strokes, the results were like magic:

1. The Neutrophils Calmed Down: Once the "Peacekeeper" got inside the neutrophils, they stopped building those sticky nets (NETs). They went from being "riot police" to "calm security guards."
2. The Tiny Roads Opened: Because the neutrophils stopped clogging the capillaries, blood could finally flow into the tiny streets.
3. The Brain Survived: The brain tissue that was about to die was saved. The area of damage was much smaller, and the mice recovered much better.

The "Double Agent" Analogy

The most exciting part of this paper is that circSCMH1 is a "Double Agent."

• Phase 1 (The Emergency): Right after the stroke, it acts as a Fire Extinguisher. It stops the inflammation and the traffic jams immediately.
• Phase 2 (The Recovery): Weeks later, it acts as a Construction Foreman. It helps rebuild the brain and grow new blood vessels.

Usually, doctors have to use one drug for the fire and a different drug for the construction. This research suggests we might be able to use one single treatment to do both jobs, simply by delivering it to the right cell at the right time.

The Bottom Line

This study solves a major puzzle in stroke treatment. It explains why some patients don't recover even after the clot is removed (because of the "traffic jam" caused by angry neutrophils). It also offers a new, clever solution: a targeted delivery system that sneaks a "Peacekeeper" molecule into the angry cells to stop the chaos immediately, while also setting the stage for long-term healing.

It's like realizing that to fix a city after a disaster, you don't just need to clear the main road; you need to hand out "calm-down" badges to the panicked crowd before they block the side streets.

Technical Summary

1. Problem Statement

Despite the success of Endovascular Thrombectomy (EVT) in recanalizing large vessels in Large Vessel Occlusion Acute Ischemic Stroke (LVO-AIS), a significant proportion of patients experience Futile Recanalization (FR). FR is characterized by the failure to achieve meaningful functional recovery despite successful macrovascular reopening.

• Pathophysiology: The primary driver of FR is post-reperfusion thromboinflammation. Upon reperfusion, infiltrating neutrophils undergo aberrant activation and release Neutrophil Extracellular Traps (NETs). This leads to microvascular thrombosis, capillary stalling, and the "no-reflow" phenomenon, preventing tissue-level reperfusion.
• Therapeutic Gap: Conventional neuroprotectants have failed clinically because they cannot address the spatiotemporal complexity of stroke. They typically target either the acute inflammatory phase or the delayed repair phase, but not both simultaneously. Furthermore, systemic delivery often fails to reach specific cellular targets (activated neutrophils) in the hyperacute phase.
• Knowledge Gap: Circular RNA circSCMH1 is known to promote late-stage neurovascular repair (angiogenesis, neuroplasticity), but its role in the hyperacute phase and its potential to modulate innate immune responses (specifically neutrophil-mediated thromboinflammation) remains unexplored.

2. Methodology

The study employed a multi-modal approach combining clinical analysis, nanomedicine engineering, and advanced in vivo imaging.

• Clinical Cohort:

  • Subjects: LVO-AIS patients undergoing mechanical thrombectomy at Zhongda Hospital.
  • Stratification: Patients were divided into Meaningful Recanalization (MR) and Futile Recanalization (FR) groups based on 3-month modified Rankin Scale (mRS) scores.
  • Samples: Thrombi and plasma were collected.
  • Analysis: qPCR for circSCMH1 levels; ELISA for NET biomarkers (H3Cit, MPO-DNA); Immunofluorescence (IF) of thrombi to visualize circSCMH1, Neutrophil Elastase (NE), and H3Cit.

• Nanomedicine Engineering:

  • Delivery System: Engineered pepLNP (peptide-targeted Lipid Nanoparticles).
  • Targeting Mechanism: Utilized a formyl peptide receptor (FPR)-targeting peptide (cFLFLF motif) to specifically bind to activated neutrophils.
  • Payload: Encapsulated mouse circSCMH1.
  • Formulation: Ionizable lipids, DSPC, cholesterol, and DSPE-PEG-pep assembled via ethanol dilution.

• Animal Models:

  • Model: Transient Middle Cerebral Artery Occlusion (tMCAO) in C57BL/6J mice.
  • Intervention: Intravenous administration of circSCMH1@pepLNP immediately post-reperfusion.
  • Controls: Vector control and non-targeted circSCMH1@LNP.

• Advanced Imaging & Assessment:

  • Histology: Nissl staining for infarct volume; Western blot/IF for thrombosis (CD41, Fibrinogen) and NETosis (NE, H3Cit) markers.
  • Dual-Lectin Labeling: Used red (pre-ischemia) and green (post-reperfusion) Lycopersicon esculentum lectins to distinguish no-reflow microvessels (labeled only by red) from recanalized vessels.
  • Intravital Two-Photon Microscopy (TPM): Real-time monitoring of neutrophil dynamics (rolling, adhesion, migration velocity, capillary stalling) through cranial windows.
  • Laser Speckle Contrast Imaging (LSCI): Quantified macroscopic cortical blood flow.

3. Key Contributions

1. Clinical Discovery: Identified that circSCMH1 is significantly downregulated in the thrombi and plasma of FR patients and negatively correlates with NET burden.
2. Mechanistic Insight: Demonstrated that low circSCMH1 levels in neutrophils are intrinsically linked to a higher propensity for NETosis, driving microvascular obstruction.
3. Novel Therapeutic Function: Uncovered a previously unknown hyperacute anti-thromboinflammatory function of circSCMH1. While previously known for late-stage repair, this study proves it can acutely suppress innate immune activation when delivered intracellularly.
4. Targeted Delivery Strategy: Developed a neutrophil-specific LNP system (pepLNP) that overcomes the delivery bottleneck, allowing circSCMH1 to reach activated neutrophils in the hyperacute phase.
5. Dual-Phase Paradigm: Proposed a "single-agent, dual-phase" therapeutic strategy where one molecule addresses both acute thromboinflammation (via neutrophil targeting) and delayed neurovascular repair.

4. Key Results

• Clinical Correlation:

  • FR patients showed significantly lower circSCMH1 levels in thrombi and plasma compared to MR patients.
  • Plasma circSCMH1 levels were negatively correlated with circulating NET biomarkers (H3Cit and MPO-DNA).
  • In thrombi, circSCMH1-negative neutrophils exhibited a significantly higher rate of NETosis (H3Cit positivity) compared to circSCMH1-positive neutrophils.

• Therapeutic Efficacy in Mice:

  • Targeting: circSCMH1@pepLNP achieved specific accumulation in peripheral blood neutrophils, confirmed by IF and qPCR.
  • Infarct Reduction: Treatment significantly reduced infarct volume at day 3 compared to controls.
  • Suppression of Thromboinflammation:
    • Reduced platelet deposition (CD41) and fibrin(ogen).
    • Markedly decreased NETosis markers (NE and H3Cit).
    • Reduced neutrophil infiltration and microthrombus formation in the ischemic cortex.
  • Restoration of Perfusion:
    • Microvascular: Dual-lectin labeling showed a significant reduction in no-reflow microvessels.
    • Macrovascular: LSCI confirmed improved cortical blood flow at days 1 and 3.
    • Dynamics: Intravital TPM revealed that treatment reduced neutrophil rolling/adhesion, increased migratory velocity, and significantly shortened the duration of capillary stalling.

• Comparison: The targeted delivery (pepLNP) was significantly superior to non-targeted delivery (LNP), highlighting the necessity of specific neutrophil targeting for efficacy.

5. Significance

• Translational Breakthrough: This study bridges the gap between preclinical neuroprotection and clinical reality by addressing the "no-reflow" phenomenon, a major cause of EVT failure.
• Redefining circSCMH1: It expands the functional landscape of circSCMH1 from a late-stage repair molecule to a critical regulator of the hyperacute immune response, offering a unified mechanism for stroke management.
• Novel Adjunctive Therapy: The proposed circSCMH1@pepLNP offers a promising adjunctive therapy for EVT. Unlike current strategies focusing solely on clot dissolution (thrombolytics) or platelet inhibition, this approach targets the neutrophil-driven inflammatory cascade that clogs the microvasculature.
• Spatiotemporal Solution: By simultaneously mitigating early thromboinflammation and preserving the molecule's inherent reparative properties, this strategy overcomes the historical failure of single-window neuroprotectants, paving the way for comprehensive stroke management.

Conclusion: The study establishes that neutrophil-specific downregulation of circSCMH1 drives futile recanalization. Targeted intracellular delivery of circSCMH1 via pepLNP unlocks a potent acute anti-thromboinflammatory function, effectively restoring microvascular perfusion and improving outcomes in stroke models, representing a paradigm shift toward dual-phase therapeutic interventions.